Microglial inflammation in the parkinsonian substantia nigra: Relationship to alpha-synuclein deposition

Journal of Neuroinflammation

Volumn 2, Issue , 2005, Pages

  Croisier, Emilie ^a   Moran, Linda B ^a   Dexter, David T ^a   Pearce, Ronald K B ^a   Graeber, Manuel B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CD68 ANTIGEN; CELL MARKER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CELL ACTIVATION; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; MACROPHAGE; MALE; MEDICAL PARAMETERS; MICROGLIA; NERVE CELL; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHAGOCYTE; SUBSTANTIA NIGRA;

EID: 27344438938     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-2-14     Document Type: Article

References (35)

1. Achim C, Auer R, Bergeron C, Cardozo A, Deprez M, de Vos R, Duyckaerts C, Egensperger R, Esiri M, Frosch MP, Giannini C, Goebel HH. Graeber MB, Graham DI. Gray F, Hilda M, Hashizume Y. Ikeda K, Ironsida JW, Kroutzberg GW, Lantos P, Lowe J, Ludwin S, Matsumoto Y. Olsson Y, Sasaki A. Schalthauer BW, Takahashi H, Tolnay M, Trojanowski JQ, Troost D, de F, Webster H: Global democratic consensus on neuropathological disease criteria. Lancet Neurol 2002, 1:340.
2. Polymeropoulos MH, Lavedan C, Leroy E. Ide SE, Dehelia A. Dutra A. Pike B,: Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasakharappa S, Athanassiadou A. Papapotropoulos T. Johnson WG. Lazzarini AM, Duvoisin RC, Di Iorio G. Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gone Identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
3. Chartier-Harlin MC, Kachergus J, Roumier C. Mouroux V, Douay X, Lincoln S. Levecque C, Larvor L, Andrieux J, Hullhan M, Waucquier N, Defebvre L. Amouyel P, Farrar M. Destee A: Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
4. Kruger R, Kuhn W. Muller T. Woitalia D. Graeber M. Kosel S, Przuntek H, Epplen JT. Schols L, Riess O; Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
5. Singleton AB, Farrer M, Johnson J, Singleton A. Hague S, Kischargus J, Hulihan M, Peuralinna T, Dutra A. Nussbaum R. Lincoln S, Crawley A, Hanson M, Maraganore D. Adler C. Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K: alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
6. Zarranz JJ, Alagre J, Gomez-Estaban JC, Lezcano E, Ros R, Ampuero I. Vidal L. Hoenicks J. Rodriguez O, Atares B, Llorens V, Gomez Tortasa E. del Sar T, Munoz DG, de Yebenez JG: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.
7. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ. Jakes R, Goedert M: Alpha-synuclein In Lewy bodies. Nature 1997, 388:839-840.
8. Parkkinen L, Soininen H. Laakso M, Alafuzoff I: Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001. 27:314-325.
9. Braak K Del Tredici K. Rub U, de Vos RAI, Jansen Steur ENH, Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003. 24:197-211.
10. Parkkinen L. Kauppinen T, Pirttila T. Autere JM, Alafuzoff I: Alpha-synuiclein pathology does not predict extrapyramidal symptoms or dementia, Ann Neurol 2005, 57:82-91.
11. McGeer PL Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR In the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
12. Moron LB. Duke DC, Turkheimer FE, Banati RB, Graeber MB: Towards a transcriptome definition of microglial cells. Neuregenetics 2004, 5:95-108.
13. Streit WI, Sammons NW, Kuhns AJ, Sparks DL: Dystrophic microglia in the aging human brain. Glia 2004, 45:208-212.
14. Grunblatt E, Mandel S, Youdim MB: Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxy. dopamine and MPTP. Ann N Y Acad Sci 2000, 899:262-273.
15. Kosel S, Egensperger R. von EU, Mehraein P, Graeber MB: On the question of apoptosis in the parkinsonian substantia nigra Acta Neuropathol (Berl) 1997, 93:105-108.
16. Vonsattel JP, Aizawa H, Ge P, DiFiglia M, McKee AC, MacDonald M, Guselia JF, Landwehrmeyer GB, Bird ED, Richard EP, et al.: An Improved approach to prepare human brains for research. J Neuropathol Exp Neurol 1995, 54:42-56.
17. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T. Hirose T: Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 2004. 63:43-52.
18. Ishizawa K. Dickson DW: Microglial activation parallels system degeneration in progressive supranuclear palsy and cortico-basal degeneration. J Neuropathol Exp Neurol 2001, 60:647-657.
19. Togo T, Iseki E, Marui W,. Akiyama H, Ueda K, Kosaka K: Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 2001, 184:71-75.
20. Rozemuller AJ, Eikelenboom P, Theeuwes JW, Jansen Steur EN, de Vos RA: Activated microglial cells and complement factors we unrelated to cortical Lewy bodies. Acta Neuropathol (Berl) 2000, 100:701-708.
21. Yasuhara O, Kawamata T, Aimi Y, McGeer EG, McGeer PL: Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases. Neurosci Lett 1994, 170:13-16.
22. Taupenot L, Ciesielski-Treska J, Ulrich G. Chasserot-Golaz S, Aunis D. Bader MF: Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neurosciance 1996, 72:377-389.
23. Orr CF, Rowe DB, Halliday GM: An Inflammatory review of Parkinson's disease. Prog Neurobiol 2002, 68:325-340.
24. Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
25. Barcia C. Sanchez Bahillo A, Fernandez-Villalba E, Bautista V. Poza Y, Poza M, Fernandez-Barrairo A, Hirsch EC, Herrero MT: Evidence of active microglia in substantia, nigra pars compacts, of Parkinson monkeys 1 year after MPTP exposure. Glia 2004, 46:402-409.
26. Hurley SD, O'Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN: Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol 2003, 184:659-668.
27. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y: Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (Berl) 2003, 106:518-526.
28. Mrak RE, Griffin ST. Graham DI: Aging-associated changes in human brain. J Neuropathol Exp Neurol 1997, 56:1269-1275.
29. Rozovsky I, Finch CE, Morgan TE: Age-related activation of microglia and astrocytes: in vitro studies show persistent phenotypes of aging, increased proliferation and resistance to down-regulation. Neurobiol Aging 1998, 19:97-103.
30. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH: Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003, 964:288-294.
31. Graeber MB: Glial inflammation in neurodegenerative diseases. In 8th Annual Congress of the British Society for Immunology, Harrogate, 5-8 December 2000, Immunology Issue Supplement Oxford: Blackwells; 2000. Abstract.
32. Cagnin A, Gerhard A. Banati RB: In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 2002, 12:581-586.
33. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R: Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003, 17:500-2.
34. Reichert F, Rotshenker S: Deficient activation of microglia during optic nerve degeneration. J Neuroimmunol 1996, 70:153-161.
35. Kosel S, Egensperger R, Bise K, Arbogast S, Mehraein P, Graeber MB: Long-lasting perivascular accumulation of major histocompatibility complex class II-positive lipophages in the spinal cord of stroke patients: possible relevance for the immune privilege of the brain. Acta Neuropathol (Berl) 1997, 94:532-538.